EUCTR2008-003610-94-PT进行中（未招募）1 期
ong-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH). - PATENT-2
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Bayer AG
- 入组人数
- 462
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients who have completed 12 weeks of treatment in the double blind trial
- •PATENT-1.
- •Patients must have given their written informed consent to participate in the
- •study after having received adequate previous information and prior to any
- •study-specific procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 4
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patient’s participating in another clinical trial
- •Patients who have an ongoing serious adverse event from PATENT-1 that is
- •assessed as related to BAY 63-2521 are not allowed to participate in the
- •extension trial.
- •Pregnant women(i.e. positive serum ß-human-chorionic-gonadotropin test or other signs of pregnancy) or breast feeding women, or women with childbearing
- •potential not using a combination of safe contraception methods.
- •Patients with a medical disorder, condition, or history of such that would impair
- •the patient's ability to participate or complete this study in the opinion of the
- •investigator or the sponsor.
- •Pertinent non compliance with the conditions for the trial or instructions by the investigator during PATENT-1 participation.
- •Patients with hypersensitivity to the investigational drug or inactive
- •constituents.
研究者
相似试验
进行中（未招募）
1 期
ong-term study to collect additional information to evaluate the safetyand tolerability of BAY 63-2521 in different dosesPulmonary Arterial Hypertension (PAH)MedDRA version: 17.0Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2008-003610-94-DKBayer HealthCare AG462
进行中（未招募）
1 期
ong-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63 2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH). - PATENT-2Pulmonary Arterial Hypertension (PAH)MedDRA version: 9.1 Level: LLT Classification code 10064911 Term: Pulmonary arterial hypertensionEUCTR2008-003610-94-FRBayer HealthCare AG462
进行中（未招募）
1 期
ong-term study to collect additional information to evaluate the safety and tolerability of BAY 63-2521 in different dosesPulmonary Arterial Hypertension (PAH)MedDRA version: 18.0 Level: PT Classification code 10064911 Term: Pulmonary arterial hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2008-003610-94-SEBayer HealthCare AG462
进行中（未招募）
不适用
ong-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH). - CHEST-2Chronic Thromboembolic Pulmonary HypertentionMedDRA version: 9.1Level: LLTClassification code 10037406Term: Pulmonary hypertension secondaryEUCTR2008-003539-19-IEBayer HealthCare AG, Bayer Vital GmbH, D-51368 Leverkusen270
进行中（未招募）
1 期
ong-term study to collect additional information to evaluate the safety and tolerability of BAY 63-2521 in different dosesChronic Thromboembolic Pulmonary HypertensionMedDRA version: 19.0Level: LLTClassification code 10037406Term: Pulmonary hypertension secondarySystem Organ Class: 100000004855EUCTR2008-003539-19-SKBayer AG270